复星医药(02196.HK)创新肿瘤免疫疗法FXB0871中国I期临床试验完成首例参与者给药

阿斯达克财经

05/29

复星医药(02196.HK) 宣布，创新肿瘤免疫疗法FXB0871在中国境内(不包括港澳台地区)的I期临床试验已完成首例参与者给药。FXB0871是复星医药与以色列Teva(TEVA.US) 合作开发的PD-1靶向型减弱IL-2融合蛋白的免疫疗法(ATTENUKINE)。这标志着该临床试验药物在中国临床开发进程中取得的一个重要里程碑，也为后续差异化免疫肿瘤联合治疗的探索奠定了关键基础。...

网页链接

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2639626872"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2639626872\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2639626872?lang=zh_CN&edition=fundamental","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20170911103105061_s.JPG","is_english":false,"pubTime":"2026-05-29 17:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2639626872","market":"sh","top_or_hot":-1,"title":"复星医药(02196.HK)创新肿瘤免疫疗法FXB0871中国I期临床试验完成首例参与者给药","media":"阿斯达克财经","content":"<div>\n<p>复星医药(02196.HK) 宣布，创新肿瘤免疫疗法FXB0871在中国境内(不包括港澳台地区)的I期临床试验已完成首例参与者给药。FXB0871是复星医药与以色列Teva(TEVA.US)  合作开发的PD-1靶向型减弱IL-2融合蛋白的免疫疗法(ATTENUKINE)。这标志着该临床试验药物在中国临床开发进程中取得的一个重要里程碑，也为后续差异化免疫肿瘤联合治疗的探索奠定了关键基础。...</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1526757/latest-news/AAFN\">网页链接</a>\n\n</div>\n","source":"aastocks_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>复星医药(02196.HK)创新肿瘤免疫疗法FXB0871中国I期临床试验完成首例参与者给药</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n复星医药(02196.HK)创新肿瘤免疫疗法FXB0871中国I期临床试验完成首例参与者给药\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-29 17:43 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1526757/latest-news/AAFN><strong>阿斯达克财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>复星医药(02196.HK) 宣布，创新肿瘤免疫疗法FXB0871在中国境内(不包括港澳台地区)的I期临床试验已完成首例参与者给药。FXB0871是复星医药与以色列Teva(TEVA.US)  合作开发的PD-1靶向型减弱IL-2融合蛋白的免疫疗法(ATTENUKINE)。这标志着该临床试验药物在中国临床开发进程中取得的一个重要里程碑，也为后续差异化免疫肿瘤联合治疗的探索奠定了关键基础。...</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1526757/latest-news/AAFN\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1593","symbol_name":"医美概念股","start_time":0,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1526757/latest-news/AAFN","article_id":"2639626872","we_media_id":null,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20170911103105061_s.JPG"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1526757/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2639626872","pubTimestamp":1780047780,"columns":[],"sourceInfo":{"source_id":"aastocks_highlight","name":"阿思達克財經"},"weMediaInfo":null,"summary":"复星医药宣布，创新肿瘤免疫疗法FXB0871在中国境内的I期临床试验已完成首例参与者给药。FXB0871是一款PD-1靶向型减弱IL-2融合蛋白免疫疗法，为一款全球前沿的创新药物。FXB0871旨在将减弱的IL-2选择性递送至PD-1阳性的T细胞，从而增强T细胞抗肿瘤活性，同时尽可能减少非靶向的系统性毒性。迄今为止，全球范围内尚无基于IL-2并可选择性靶向递送至肿瘤反应性T细胞的药品获批上市。目前，TEV-56278/FXB0871的国际多中心I期临床研究正在美国及加拿大开展。","collect":0,"end_time":0,"defaultTopTitle":"aastocks.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"600196":"复星医药","BK1593":"医美概念股","BK0175":"白马股","BK0196":"行业龙头","BK1515":"抗疫概念","BK0012":"证金概念","BK0187":"一线龙头","BK0060":"抗癌","02196":"复星医药","BK1191":"制药","BK0188":"融资融券","BK0028":"国家队","BK0239":"医药制造","BK0183":"MSCI概念","BK0096":"民营医院"},"translate_title":"Fosun Pharma (02196.HK) Phase I clinical trial of innovative tumor immunotherapy FXB0871 in China completes first participant dosing","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600196":1.5,"02196":1.5},"content_text":"复星医药(02196.HK) 宣布，创新肿瘤免疫疗法FXB0871在中国境内(不包括港澳台地区)的I期临床试验已完成首例参与者给药。FXB0871是复星医药与以色列Teva(TEVA.US)  合作开发的PD-1靶向型减弱IL-2融合蛋白的免疫疗法(ATTENUKINE)。这标志着该临床试验药物在中国临床开发进程中取得的一个重要里程碑，也为后续差异化免疫肿瘤联合治疗的探索奠定了关键基础。FXB0871(复星医药权益范围外药物名称为TEV-56278)是一款PD-1靶向型减弱IL-2融合蛋白免疫疗法(ATTENUKINETM)，为一款全球前沿的创新药物。FXB0871旨在将减弱的IL-2选择性递送至PD-1阳性的T细胞，从而增强T细胞抗肿瘤活性，同时尽可能减少非靶向的系统性毒性。临床前研究数据显示，该药物可实现肿瘤消退、增强T细胞浸润并形成持久的免疫记忆。迄今为止，全球范围内尚无基于IL-2并可选择性靶向递送至肿瘤反应性T细胞的药品获批上市。根据双方此前达成的协议，复星医药拥有该产品在中国及约定的东南亚国家的独家开发、生产和商业化权利，双方将共享临床数据，共同加速这一创新疗法的研发进展。目前，TEV-56278/FXB0871的国际多中心I期临床研究正在美国及加拿大开展。(da/a)(港股报价延迟最少十五分钟。沽空资料截至 2026-05-29 16:25。) (美股为即时串流报价； OTC市场股票除外，资料延迟最少15分钟。)AASTOCKS新闻","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}